{
    "Allocation": "N/A",
    "CompleteTime": 36,
    "DesignModel": "Single Group Assignment",
    "DrugInformation": {
        "ArmGroupList": [
            {
                "ArmGroupDescription": "pembrolizumab+cisplatin + 5-fluorouracil: 3000mg/m (qd d1-d3) ivgtt, ",
                "ArmGroupLabel": "pembrolizumab+cisplatin + 5-fluorouracil",
                "ArmGroupType": "Experimental",
                "InterventionDescription": [
                    {
                        "Dosage": "3000mg/m",
                        "DrugName": "pembrolizumab+cisplatin + 5-fluorouracil",
                        "Duration": "(qd d1-d3)",
                        "HowToTake": "ivgtt"
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "Drug: pembrolizumab+cisplatin + 5-fluorouracil"
                    ]
                }
            }
        ]
    },
    "Enrollment": "60",
    "InterventionName": "pembrolizumab+cisplatin + 5-fluorouracil",
    "Masking": "None (Open Label)",
    "NCTID": "NCT05446467",
    "Objective": "Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC",
    "OfficialTitle": "Safety and Efficacy of Pembrolizumab in Combination With Low-dose PF (Cisplatin and 5-Fluorouracil) as Neoadjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Multi-center, Single-arm Clinical Study Trial",
    "PopulationBox": {
        "Condition": "Head and Neck Squamous Cell Carcinoma",
        "Gender": "All",
        "HealthyCondition": "No",
        "MaxAge": "85 Years",
        "MinAge": "18 Years",
        "Participant": "60"
    },
    "PopulationRatio": "",
    "Title": "Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC",
    "WashoutPeriod": ""
}